← All trials
NCT02197221
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2015
- Primary completion
- Jan 1, 2020
- Completion date
- Sep 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 300
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of ToulouseLead sponsor
- University of AntwerpOverall official - principal investigator
- University of GrenobleOverall official - principal investigator
- University of LyonOverall official - principal investigator
- Centre hospitalier de MulhouseOverall official - principal investigator
- CHR ORLEANSOverall official - principal investigator
- CH DUNKERQUEOverall official - principal investigator
- University of NantesOverall official - principal investigator
- University of LimogesOverall official - principal investigator
- University of Nice Sophia AntipolisOverall official - principal investigator
- University of PoitiersOverall official - principal investigator
- University of RennesOverall official - principal investigator
- CH BAYONNEOverall official - principal investigator
- Université de La RéunionOverall official - principal investigator
- CHU ST PRIEST EN JAREZOverall official - principal investigator
- University of VersaillesOverall official - principal investigator
- Hospital AvicenneOverall official - principal investigator
- CHU Henri MondorOverall official - principal investigator
- University of ReimsOverall official - principal investigator
- University of Picardie Jules VerneOverall official - principal investigator
- Centre Henri BecquerelOverall official - principal investigator
- CH ArgenteuilOverall official - principal investigator
- University of Caen-NormandieOverall official - principal investigator
- University of ToulouseOverall official - principal investigator
- University of LorraineOverall official - principal investigator
- Government of FranceCollaborator
- Curie InstituteOverall official - principal investigator
- Institut Paoli-CalmettesOverall official - principal investigator
- Janssen Pharmaceutica NVCollaborator
- University of LilleOverall official - principal investigator
- University of BordeauxOverall official - principal investigator
- University of BurgundyOverall official - principal investigator
- University of Franche-ComtéOverall official - principal investigator
- University of Western BrittanyOverall official - principal investigator
- François Rabelais UniversityOverall official - principal investigator
- University Clermont AuvergneOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.